Defective signalling pathway sheds light on cystic fibrosis

In a study that could lead to new therapeutic targets for patients with the cystic fibrosis, a research team from the University of California, San Diego School of Medicine has identified a defective signalling pathway that contributes to disease severity. In the study, published in the journal Nature Medicine, the researchers report that defective signalling for a protein called the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) accounts for a portion of disease symptoms in cystic fibrosis, and that correction of the defective pathway reduces symptoms of the disease in mice...

Read the whole article on

More from